The DOI matches its Crossref record; 142 of the 142 references it cites were found in a registry or an index.
Battling Chemoresistance in Cancer: Root Causes and Strategies to Uproot Them
Open accessAbstract
With nearly 10 million deaths, cancer is the leading cause of mortality worldwide. Along with major key parameters that control cancer treatment management, such as diagnosis, resistance to the classical and new chemotherapeutic reagents continues to be a significant problem. Intrinsic or acquired chemoresistance leads to cancer recurrence in many cases that eventually causes failure in the successful treatment and death of cancer patients. Various determinants, including tumor heterogeneity and tumor microenvironment, could cause chemoresistance through a diverse range of mechanisms. In this review, we summarize the key determinants and the underlying mechanisms by which chemoresistance appears. We then describe which strategies have been implemented and studied to combat such a lethal phenomenon in the management of cancer treatment, with emphasis on the need to improve the early diagnosis of cancer complemented by combination therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699
Comprehensive molecular profiling of lung adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13385 · Cited by 5,732
Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer
Soria, J.-C., Ohe, Y., Vansteenkiste, J., Reungwetwattana, T., Chewaskulyong, B., Lee, K. H., Dechaphunkul, A., Imamura, F., Nogami, N., Kurata, T., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1713137 · Cited by 5,508
Comprehensive genomic characterization of squamous cell lung cancers
The Cancer Genome Atlas Research Network (2012) · Nature · doi:10.1038/nature11404 · Cited by 3,994
Targeting multidrug resistance in cancer
Szakács, G., Paterson, J. K., Ludwig, J. A., Booth-Genthe, C., & Gottesman, M. M. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1984 · Cited by 3,609 · cited 1×
“Importantly, dysregulation of thymidylate synthase [1], dihydrofolate reductase [2,3] and topoisomerases I and II [4,5] are known to cause resistance against 5-fluorouracil and tomudex [6], methotrexate [7] and doxorubicin [8], respectively.”
BackgroundClinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104
Cancer and Radiation Therapy: Current Advances and Future Directions
Baskar, R., Lee, K. A., Yeo, R., & Yeoh, K.-W. (2012) · International Journal of Medical Sciences · doi:10.7150/ijms.3635 · Cited by 2,880
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
Moore, K., Colombo, N., Scambia, G., Kim, B.-G., Oaknin, A., Friedlander, M., Lisyanskaya, A., Floquet, A., Leary, A., Sonke, G. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1810858 · Cited by 2,870
Liquid biopsies come of age: Towards implementation of circulating tumour DNA
Wan, J. C. M., Massie, C., Garcia-Corbacho, J., Mouliere, F., Brenton, J. D., Caldas, C., Pacey, S., Baird, R., & Rosenfeld, N. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.7 · Cited by 2,809
A view on drug resistance in cancer
Vasan, N., Baselga, J., & Hyman, D. M. (2019) · Nature · doi:10.1038/s41586-019-1730-1 · Cited by 2,770
The emerging role of lncRNAs in cancer
Huarte, M. (2015) · Nature Medicine · doi:10.1038/nm.3981 · Cited by 2,702
Alectinib versus Crizotinib in Untreated ALK -Positive Non–Small-Cell Lung Cancer
Peters, S., Camidge, D. R., Shaw, A. T., Gadgeel, S., Ahn, J. S., Kim, D.-W., Ou, S.-H. I., Pérol, M., Dziadziuszko, R., Rosell, R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1704795 · Cited by 2,527
Drug resistance in cancer: An overview
Housman, G., Byler, S., Heerboth, S., Lapinska, K., Longacre, M., Snyder, N., & Sarkar, S. (2014) · Cancers · doi:10.3390/cancers6031769 · Cited by 2,463
Strategies and challenges for the next generation of antibody–drug conjugates
Beck, A., Goetsch, L., Dumontet, C., & Corvaïa, N. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.268 · Cited by 2,271
Zheng, X., Carstens, J. L., Kim, J., Scheible, M., Kaye, J., Sugimoto, H., Wu, C.-C., LeBleu, V. S., & Kalluri, R. (2015) · Nature · doi:10.1038/nature16064 · Cited by 2,032
Non-coding RNA networks in cancer
Anastasiadou, E., Jacob, L. S., & Slack, F. J. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2017.99 · Cited by 1,884
The Different Mechanisms of Cancer Drug Resistance: A Brief Review
Mansoori, B., Mohammadi, A., Davudian, S., Shirjang, S., & Baradaran, B. (2017) · Advanced Pharmaceutical Bulletin · doi:10.15171/apb.2017.041 · Cited by 1,883
Fischer, K. R., Durrans, A., Lee, S., Sheng, J., Li, F., Wong, S. T. C., Choi, H., El Rayes, T., Ryu, S., Troeger, J., et al. (2015) · Nature · doi:10.1038/nature15748 · Cited by 1,791
Tumor microenvironment complexity and therapeutic implications at a glance
Baghban, R., Roshangar, L., Jahanban-Esfahlan, R., Seidi, K., Ebrahimi-Kalan, A., Jaymand, M., Kolahian, S., Javaheri, T., & Zare, P. (2020) · Cell Communication and Signaling · doi:10.1186/s12964-020-0530-4 · Cited by 1,784 · cited 2×
“Drug influx SLC transporters Pralatrexate and methotrexate ALL, multiple myeloma, Osteosarcoma [62,63,79]”
BackgroundMechanisms of Multidrug Resistance in Cancer Chemotherapy
Bukowski, K., Kciuk, M., & Kontek, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093233 · Cited by 1,757
Citron, M. L., Berry, D. A., Cirrincione, C., Hudis, C., Winer, E. P., Gradishar, W. J., Davidson, N. E., Martino, S., Livingston, R., Ingle, J. N., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.09.081 · Cited by 1,564
Nanoparticle Delivery of Cancer Drugs
Wang, A. Z., Langer, R., & Farokhzad, O. C. (2012) · Annual Review of Medicine · doi:10.1146/annurev-med-040210-162544 · Cited by 1,561
The role of glutathione-S-transferase in anti-cancer drug resistance
Townsend, D. M., & Tew, K. D. (2003) · Oncogene · doi:10.1038/sj.onc.1206940 · Cited by 1,353
DQIS Research Group (2026) · PubMed · doi:10.5281/zenodo.21937949 · Cited by 1,327
Drug resistance and combating drug resistance in cancer
Wang, X., Zhang, H., & Chen, X. (2019) · Cancer Drug Resistance · doi:10.20517/cdr.2019.10 · Cited by 1,085
Ten-Year Risk of False Positive Screening Mammograms and Clinical Breast Examinations
Elmore, J. G., Barton, M. B., Moceri, V. M., Polk, S., Arena, P. J., & Fletcher, S. W. (1998) · New England Journal of Medicine · doi:10.1056/nejm199804163381601 · Cited by 1,053
Noncoding RNA:RNA Regulatory Networks in Cancer
Chan, J. J., & Tay, Y. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19051310 · Cited by 1,033
Skipper, H. E., Schabel, F. M., & Wilcox, W. S. (1964) · PubMed · Cited by 904
Laird, A. K. (1964) · British Journal of Cancer · doi:10.1038/bjc.1964.55 · Cited by 863
Systems biology of cisplatin resistance: past, present and future
Galluzzi, L., Vitale, I., Michels, J., Brenner, C., Szabadkai, G., Harel-Bellan, A., Castedo, M., & Kroemer, G. (2014) · Cell Death & Disease · doi:10.1038/cddis.2013.428 · Cited by 782 · cited 1×
“The resistance to doxorubicin [5], paclitaxel [6–8], 5-fluorouracil [9], cyclophosphamide [10,11] and carboplatin [12] have been shown to cause cancer recurrence in breast cancer associated with poorer prognosis and shorter survival.”
Background5-Fluorouracil: Mechanisms of Resistance and Reversal Strategies
Zhang, N., Yin, Y., Xu, S.-J., & Chen, W.-S. (2008) · Molecules · doi:10.3390/molecules13081551 · Cited by 771
Mechanisms of chemoresistance in cancer stem cells
Abdullah, L. N., & Chow, E. K. (2013) · Clinical and Translational Medicine · doi:10.1186/2001-1326-2-3 · Cited by 721
The role and mechanisms of action of microRNAs in cancer drug resistance
Si, W., Shen, J., Zheng, H., & Fan, W. (2019) · Clinical Epigenetics · doi:10.1186/s13148-018-0587-8 · Cited by 668
Resistance to cancer chemotherapy: failure in drug response from ADME to P-gp
Alfarouk, K. O., Stock, C.-M., Taylor, S., Walsh, M., Muddathir, A. K., Verduzco, D., Bashir, A. H. H., Mohammed, O. Y., Elhassan, G. O., Harguindey, S., et al. (2015) · Cancer Cell International · doi:10.1186/s12935-015-0221-1 · Cited by 665
Benefits and Harms of Breast Cancer Screening: A Systematic Review
Myers, E. R., Moorman, P., Gierisch, J. M., Havrilesky, L. J., Grimm, L. J., Ghate, S., Davidson, B., Mongtomery, R. C., Crowley, M. J., McCrory, D. C., et al. (2015) · JAMA · doi:10.1001/jama.2015.13183 · Cited by 637
The molecular mechanisms of chemoresistance in cancers
Zheng, H.-C. (2017) · Oncotarget · doi:10.18632/oncotarget.19048 · Cited by 624
Microarray technology: beyond transcript profiling and genotype analysis
Hoheisel, J. D. (2006) · Nature Reviews Genetics · doi:10.1038/nrg1809 · Cited by 546
Recent advances in apoptosis, mitochondria and drug resistance in cancer cells
Indran, I. R., Tufo, G., Pervaiz, S., & Brenner, C. (2011) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2011.03.010 · Cited by 526
Choi, C.-H. (2005) · Cancer Cell International · doi:10.1186/1475-2867-5-30 · Cited by 523
Katsumata, N., Yasuda, M., Isonishi, S., Takahashi, F., Michimae, H., Kimura, E., Aoki, D., Jobo, T., Kodama, S., Terauchi, F., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70363-2 · Cited by 480
Significance of multiple mutations in cancer
Loeb, K. R., & Loeb, L. A. (2000) · Carcinogenesis · doi:10.1093/carcin/21.3.379 · Cited by 459
Recent Advances in Cancer Therapy: An Overview
Urruticoechea, A., Alemany, R., Balart, J., Villanueva, A., Vinals, F., & Capella, G. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210789941847 · Cited by 446
Cancer stem cells and chemoresistance: The smartest survives the raid
Zhao, J. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.02.008 · Cited by 437
ABC transporters as mediators of drug resistance and contributors to cancer cell biology
Fletcher, J. I., Williams, R. T., Henderson, M. J., Norris, M. D., & Haber, M. (2016) · Drug Resistance Updates · doi:10.1016/j.drup.2016.03.001 · Cited by 423
Martin, R. M., Donovan, J. L., Turner, E. L., Metcalfe, C., Young, G. J., Walsh, E. I., Lane, J. A., Noble, S., Oliver, S. E., Evans, S., et al. (2018) · JAMA · doi:10.1001/jama.2018.0154 · Cited by 415
Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity.
Xu, Y., & Villalona-Calero, M. A. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf337 · Cited by 413
Gray, R., Bradley, R., Braybrooke, J., Liu, Z., Peto, R., Davies, L., Dodwell, D., McGale, P., Pan, H., Taylor, C., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)33137-4 · Cited by 400
ABC Transporters in Cancer Stem Cells: Beyond Chemoresistance
Begicevic, R.-R., & Falasca, M. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18112362 · Cited by 395
DNA Repair Pathways in Cancer Therapy and Resistance
Li, L.-Y., Guan, Y.-D., Chen, X.-S., Yang, J.-M., & Cheng, Y. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.629266 · Cited by 383 · cited 1×
“Moreover, abnormal DNA repair activity was found in palbociclib (CDK4/6 inhibitor)-resistant breast cancer cells, whereas PARP inhibitors, olaparib and niraparib treatment could significantly inhibit palbociclib resistance in cancer cells [98,99].”
BackgroundPredicting the course of Gompertzian growth
NORTON, L., SIMON, R., BRERETON, H. D., & BOGDEN, A. E. (1976) · Nature · doi:10.1038/264542a0 · Cited by 306
Johnston, S. R. D., Saccani‐Jotti, G., Smith, I. E., Salter, J., Newby, J. C., Coppen, M. J., Ebbs, S. R., & Dowsett, M. (1995) · PubMed · Cited by 301
The role of exosomes and miRNAs in drug‐resistance of cancer cells
Bach, D., Hong, J., Park, H. J., & Lee, S. K. (2017) · International Journal of Cancer · doi:10.1002/ijc.30669 · Cited by 296
Zhao, F., Xiao, C., Evans, K. S., Theivanthiran, T., DeVito, N., Holtzhausen, A., Liu, J., Liu, X., Boczkowski, D., Nair, S., et al. (2018) · Immunity · doi:10.1016/j.immuni.2017.12.004 · Cited by 289
Ippolito, L., Morandi, A., Taddei, M. L., Parri, M., Comito, G., Iscaro, A., Raspollini, M. R., Magherini, F., Rapizzi, E., Masquelier, J., et al. (2019) · Oncogene · doi:10.1038/s41388-019-0805-7 · Cited by 287
Micromarkers: miRNAs in cancer diagnosis and prognosis
Ferracin, M., Veronese, A., & Negrini, M. (2010) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.10.11 · Cited by 266
Implications of micro-RNA profiling for cancer diagnosis
Cummins, J. M., & Velculescu, V. E. (2006) · Oncogene · doi:10.1038/sj.onc.1209914 · Cited by 266
Taxane resistance in breast cancer: mechanisms, predictive biomarkers and circumvention strategies.
Murray, S., Briasoulis, E., Linardou, H., Bafaloukos, D., & Papadimitriou, C. (2012) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.02.011 · Cited by 261 · cited 1×
“Importantly, dysregulation of thymidylate synthase [1], dihydrofolate reductase [2,3] and topoisomerases I and II [4,5] are known to cause resistance against 5-fluorouracil and tomudex [6], methotrexate [7] and doxorubicin [8], respectively.”
BackgroundTherapies targeting cancer stem cells: Current trends and future challenges
Dragu, D. L. (2015) · World Journal of Stem Cells · doi:10.4252/wjsc.v7.i9.1185 · Cited by 257
Circulating tumor DNA as an early cancer detection tool
Campos-Carrillo, A., Weitzel, J. N., Sahoo, P., Rockne, R., Mokhnatkin, J. V., Murtaza, M., Gray, S. W., Goetz, L., Goel, A., Schork, N., et al. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107458 · Cited by 248
SNPs in cancer research and treatment
Erichsen, H. C., & Chanock, S. J. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601574 · Cited by 245
Hepatic Arterial Infusion after Liver Resection
Kemeny, N. E., & Gonen, M. (2005) · New England Journal of Medicine · doi:10.1056/nejm200502173520723 · Cited by 237
Meng, J., Guo, F., Xu, H., Liang, W., Wang, C., & Yang, X.-D. (2016) · Scientific Reports · doi:10.1038/srep22390 · Cited by 236
The analysis of doxorubicin resistance in human breast cancer cells using antibody microarrays
Smith, L., Watson, M. B., O'Kane, S. L., Drew, P. J., Lind, M. J., & Cawkwell, L. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0190 · Cited by 235
Wickström, M., Dyberg, C., Milosevic, J., Einvik, C., Calero, R., Sveinbjörnsson, B., Sandén, E., Darabi, A., Siesjö, P., Kool, M., et al. (2015) · Nature Communications · doi:10.1038/ncomms9904 · Cited by 229
Drug Resistance in Non-Small Cell Lung Cancer: A Potential for NOTCH Targeting?
Sosa Iglesias, V., Giuranno, L., Dubois, L. J., Theys, J., & Vooijs, M. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00267 · Cited by 229
Cancer drug resistance induced by EMT: novel therapeutic strategies
De Las Rivas, J., Brozovic, A., Izraely, S., Casas-Pais, A., Witz, I. P., & Figueroa, A. (2021) · Archives of Toxicology · doi:10.1007/s00204-021-03063-7 · Cited by 229
Best, S. A., De Souza, D. P., Kersbergen, A., Policheni, A. N., Dayalan, S., Tull, D., Rathi, V., Gray, D. H., Ritchie, M. E., McConville, M. J., et al. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.02.006 · Cited by 217
Sládek, N. E., Kollander, R., Sreerama, L., & Kiang, D. T. (2002) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-001-0412-4 · Cited by 212
Intrinsic and Acquired Drug Resistance in Malignant Tumors
Lippert, T. H., Ruoff, H. J., & Volm, M. (2011) · Arzneimittelforschung · doi:10.1055/s-0031-1296504 · Cited by 202
Molecular and cellular paradigms of multidrug resistance in cancer
Vaidya, F. U., Sufiyan Chhipa, A., Mishra, V., Gupta, V. K., Rawat, S. G., Kumar, A., & Pathak, C. (2022) · Cancer Reports · doi:10.1002/cnr2.1291 · Cited by 197
Natural products to prevent drug resistance in cancer chemotherapy: a review
Yuan, R., Hou, Y., Sun, W., Yu, J., Liu, X., Niu, Y., Lu, J., & Chen, X. (2017) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13387 · Cited by 196
The roles of glucose metabolic reprogramming in chemo- and radio-resistance
Lin, J., Xia, L., Liang, J., Han, Y., Wang, H., Oyang, L., Tan, S., Tian, Y., Rao, S., Chen, X., et al. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1214-z · Cited by 189
Sensitization of Drug Resistant Cancer Cells: A Matter of Combination Therapy
Leary, M., Heerboth, S., Lapinska, K., & Sarkar, S. (2018) · Cancers · doi:10.3390/cancers10120483 · Cited by 165
Targeting Cancer Stem Cells to Overcome Chemoresistance
Nunes, T., Hamdan, D., Lebœuf, C., Bouchtaoui, M. E., Gapihan, G., Nguyen, T. T. N., Meles, S., Angeli, E., Ratajczak, P., Lu, H., et al. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19124036 · Cited by 164
Resistance mechanisms to cancer chemotherapy
Redmond, K. M., Wilson, T. R., Johnston, P. G., & Longley, D. B. (2008) · Frontiers in bioscience · doi:10.2741/3070 · Cited by 161
Meeting the Challenge of Targeting Cancer Stem Cells
Turdo, A., Veschi, V., Gaggianesi, M., Chinnici, A., Bianca, P., Todaro, M., & Stassi, G. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00016 · Cited by 161
Cancer chemoresistance; biochemical and molecular aspects: a brief overview
Kachalaki, S., Ebrahimi, M., Khosroshahi, L. M., Mohammadinejad, S., & Baradaran, B. (2016) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2016.03.025 · Cited by 159
Epithelial-mesenchymal transition and drug resistance in breast cancer (Review)
Huang, J., Li, H., & Ren, G. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.3084 · Cited by 156
LncRNA UCA1 in anti-cancer drug resistance
Wang, H., Guan, Z., He, K., Qian, J., Cao, J., & Teng, L. (2017) · Oncotarget · doi:10.18632/oncotarget.18344 · Cited by 155
Harris, L. N., Broadwater, G., Lin, N., Miron, A., Schnitt, S. J., Cowan, D., Lara, J. F., Bleiweiss, I. J., Berry, D. A., Ellis, M. J., et al. (2006) · Breast Cancer Research · doi:10.1186/bcr1622 · Cited by 154
Ferroptosis: An emerging approach for targeting cancer stem cells and drug resistance
Elgendy, S. M., Alyammahi, S. K., Alhamad, D. W., Abdin, S. M., & Omar, H. A. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103095 · Cited by 140
Combined Inhibition of STAT3 and DNA Repair in Palbociclib-Resistant ER-Positive Breast Cancer
Kettner, N. M., Vijayaraghavan, S., Durak, M. G., Bui, T. N., Kohansal, M., Ha, M. J., Liu, B., Rao, X., Wang, J., Yi, M., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3274 · Cited by 135
Jeong, Y., Hellyer, J. A., Stehr, H., Hoang, N. T., Niu, X., Das, M. S., Padda, S. K., Ramchandran, K. J., Neal, J. W., Wakelee, H. A., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1237 · Cited by 134
Huang, D., Duan, H., Huang, H., Tong, X., Han, Y. K., Ru, G., Qu, L., Shou, C., & Zhao, Z. (2016) · Scientific Reports · doi:10.1038/srep20502 · Cited by 133
Cancer stem cells in hepatocellular carcinoma: an overview and promising therapeutic strategies
Wang, N., Wang, S., Li, M., Hu, B., Liu, L., Yang, S., Yang, S., Gong, Z., Lai, P. B. S., & Chen, G. G. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835918816287 · Cited by 117
Combination therapy based on nano codelivery for overcoming cancer drug resistance
Wang, H., & Huang, Y. (2020) · Medicine in Drug Discovery · doi:10.1016/j.medidd.2020.100024 · Cited by 115
Singh, S. K., Lillard, J. W., & Singh, R. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.04.017 · Cited by 113
Peters, W. P., Rosner, G. L., Vredenburgh, J. J., Shpall, E. J., Crump, M., Richardson, P. G. G., Schuster, M. W., Marks, L. B., Cirrincione, C., Norton, L., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.10.202 · Cited by 106
Platinum drugs in the treatment of non-small-cell lung cancer
Cosaert, J. G. C. E., & Quoix, É. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600540 · Cited by 105
Huang, W.-C., Kuo, K.-T., Wang, C., Yeh, C., & Wang, Y. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1166-3 · Cited by 104
A New View of Pathway-Driven Drug Resistance in Tumor Proliferation
Nussinov, R., Tsai, C., & Jang, H. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.02.001 · Cited by 101
Therapeutic approaches targeting cancer stem cells
Zhu, C., Pan, Y., Ma, S., Cao, K., Zhou, S., Zhao, A., Li, M., & Qian, F. (2018) · Journal of Cancer Research and Therapeutics · doi:10.4103/jcrt.jcrt_976_17 · Cited by 101
Epithelial-mesenchymal transition: potential regulator of ABC transporters in tumor progression
Jiang, Z., Sun, Y., Wang, S., & Ruan, J. (2017) · Journal of Cancer · doi:10.7150/jca.19079 · Cited by 94
Cytokines, breast cancer stem cells (BCSCs) and chemoresistance
Chen, W., Qin, Y., & Liu, S. (2018) · Clinical and Translational Medicine · doi:10.1186/s40169-018-0205-6 · Cited by 92
Overcome Cancer Cell Drug Resistance Using Natural Products
Wang, P., Yang, H., Yang, Y. J., Wang, L., & Lee, S. C. (2015) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2015/767136 · Cited by 91
APC loss affects DNA damage repair causing doxorubicin resistance in breast cancer cells
Stefanski, C. D., Keffler, K., McClintock, S., Milac, L., & Prosperi, J. R. (2019) · Neoplasia · doi:10.1016/j.neo.2019.09.002 · Cited by 87
Current Status of Methods to Assess Cancer Drug Resistance
Lippert, T. H., Ruoff, H. J., & Volm, M. (2011) · International Journal of Medical Sciences · doi:10.7150/ijms.8.245 · Cited by 81
Yang, H., Zhu, R., Zhao, X., Liu, L., Zhou, Z., Zhao, L., Liang, B., Ma, W., Zhao, J., Liu, J., et al. (2019) · Oncogene · doi:10.1038/s41388-019-0764-z · Cited by 79
Oral administration of protein nanoparticles: An emerging route to disease treatment
Sadeghi, S., Lee, W. K., Kong, S. N., Shetty, A., & Drum, C. L. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104685 · Cited by 77
Self-citationThe Cancer Genome Atlas Research Network: A Sight to Behold
Giordano, T. J. (2014) · Endocrine Pathology · doi:10.1007/s12022-014-9345-4 · Cited by 72
Paredes, F., Sheldon, K. L., Lassegue, B. P., Williams, H. C., Faidley, E. A., Benavides, G. A., Torres, G., Sanhueza‐Olivares, F., Yeligar, S. M., Griendling, K. K., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1720693115 · Cited by 71
Role of membrane-embedded drug efflux ABC transporters in the cancer chemotherapy
Gupta, S. K., Singh, P., Ali, V., & Verma, M. (2020) · Oncology Reviews · doi:10.4081/oncol.2020.448 · Cited by 71
LTAN, B., Yokobori, T., Ide, M., Bai, T., Yanoma, T., Kimura, A., Kogure, N., Suzuki, M., Bao, P., Mochiki, E., et al. (2016) · Anticancer Research · doi:10.21873/anticanres.11094 · Cited by 70
Implications of ABCG2 Expression on Irinotecan Treatment of Colorectal Cancer Patients: A Review
Nielsen, D. L., Palshof, J. A., Brünner, N., Stenvang, J., & Viuff, B. M. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18091926 · Cited by 69
Chen, Y., Song, Y., Mi, Y., Jin, H., Cao, J., Li, H., Han, L., Huang, T., Zhang, X., Ren, S., et al. (2020) · APOPTOSIS · doi:10.1007/s10495-019-01588-y · Cited by 69
Evidence for Cell Adhesion-Mediated Drug Resistance of Multiple Myeloma Cells in Vivo
Schmidmaier, R., Mörsdorf, K., Baumann, P., Emmerich, B., & Meinhardt, G. (2006) · The International Journal of Biological Markers · doi:10.1177/172460080602100404 · Cited by 68
Natural Polyphenols in Cancer Chemoresistance
Hussain, S. A., Sulaiman, A. A., Balch, C., Chauhan, H., Alhadidi, Q., & Tiwari, A. K. (2016) · Nutrition and Cancer · doi:10.1080/01635581.2016.1192201 · Cited by 67
FOXM 1 mediates resistance to docetaxel in gastric cancer via up‐regulating Stathmin
Li, X., Yao, R., Lu, Y., Qiu, W., Qi, W., Liu, S., Yao, Y., & Liang, J. (2014) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12216 · Cited by 64
Counteracting Chemoresistance with Metformin in Breast Cancers: Targeting Cancer Stem Cells
Samuel, S. M., Varghese, E., Koklesová, L., Líšková, A., Kubatka, P., & Büsselberg, D. (2020) · Cancers · doi:10.3390/cancers12092482 · Cited by 60
Current Opinions on Chemoresistance: An Overview
Hasan, S., Taha, R. Y., & Omri, H. E. (2018) · Bioinformation · doi:10.6026/97320630014080 · Cited by 59
van Treijen, M. J. C., Korse, C. M., van Leeuwaarde, R. S., Saveur, L. J., Vriens, M. R., Verbeek, W. H. M., Tesselaar, M. E. T., & Valk, G. D. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00740 · Cited by 59
Wang, X., Xu, Z., Sun, J., Lv, H., Wang, Y., Ni, Y., Chen, S., Hu, C., Wang, L., Chen, W., et al. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15055 · Cited by 57
Yi, M., Cai, J., Li, J., Chen, S., Zeng, Z., Peng, Q., Ban, Y., Zhou, Y., Li, X., Xiong, W., et al. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.26410 · Cited by 56
Utility of Incorporating Genetic Variants for the Early Detection of Prostate Cancer
Nam, R. K., Zhang, W., Trachtenberg, J., Seth, A. K., Klotz, L. H., Stanimirovic, A., Punnen, S., Venkateswaran, V., Toi, A., Loblaw, D. A., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1593 · Cited by 53
Epithelial-to-mesenchymal transition and drug resistance: transitioning away from death
Song, K.-A., & Faber, A. C. (2019) · Journal of Thoracic Disease · doi:10.21037/jtd.2019.06.11 · Cited by 51
Long non-coding RNA: A recently accentuated molecule in chemoresistance in cancer
Yang, P., Tang, D., Zhao, M., Kajiyama, H., Kikkawa, F., & Kondo, Y. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09910-w · Cited by 50
Amin, A. D., Rajan, S. S., Liang, W. S., Pongtornpipat, P., Groysman, M. J., Tapia, E. O., Peters, T. L., Cuyugan, L., Adkins, J. R., Rimsza, L. M., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3437 · Cited by 48
Molecular alterations contributing to pancreatic cancer chemoresistance
Rajabpour, A., Rajaei, F., & Teimoori‐Toolabi, L. (2016) · Pancreatology · doi:10.1016/j.pan.2016.12.013 · Cited by 45
Ohata, Y., Shimada, S., Akiyama, Y., Mogushi, K., Nakao, K., Matsumura, S., Aihara, A., Mitsunori, Y., Ban, D., Ochiai, T., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0728 · Cited by 44
Non-Coding RNAs: Uncharted Mediators of Thyroid Cancer Pathogenesis
Tabatabaeian, H., Yang, S. P., & Tay, Y. (2020) · Cancers · doi:10.3390/cancers12113264 · Cited by 44
Self-citationIntrinsic Resistance to Chemotherapy in Breast Cancer
Moulder, S. (2010) · Women s Health · doi:10.2217/whe.10.60 · Cited by 42
Importance of the Keap1-Nrf2 pathway in NSCLC: Is it a possible biomarker? (Review)
Rodríguez, R. B. (2018) · Biomedical Reports · doi:10.3892/br.2018.1143 · Cited by 42
Hu, Y., Su, Y., Lei, X., Zhao, H., Wang, L., Xu, T., Guo, J., Yang, W., & Zhang, X. (2020) · Scientific Reports · doi:10.1038/s41598-020-70913-2 · Cited by 42
Gray, M. D., Mann, M. J., Nitiss, J. L., & Hendershot, L. M. (2005) · Molecular Pharmacology · doi:10.1124/mol.105.014753 · Cited by 41
Metabolic Regulation in Mitochondria and Drug Resistance
Pan, Y., Cao, M., Liu, J., Yang, Q. K., Miao, X., Go, V. L. W., Lee, P. W. N., & Xiao, G. G. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-981-10-6674-0_11 · Cited by 34
Approaches for targeting cancer stem cells drug resistance
Rosa, R., D’Amato, V., Placido, S. D., & Bianco, R. (2016) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2016.1243525 · Cited by 27
Action of bleomycin is affected by bleomycin hydrolase but not by caveolin-1
Chen, J., Chen, Y., & He, Q. (2012) · International Journal of Oncology · doi:10.3892/ijo.2012.1668 · Cited by 26
Fluctuating expression of miR-584 in primary and high-grade gastric cancer
Ghahnavieh, L. E., Tabatabaeian, H., Ghahnavieh, Z. E., Honardoost, M. A., Azadeh, M., Bistgani, M. M., & Ghaedi, K. (2020) · BMC Cancer · doi:10.1186/s12885-020-07116-5 · Cited by 26
Self-citationResistance to cis- and carboplatin initiated by epigenetic changes in ovarian cancer patients
Schwarzenbach, H., & Gahan, P. B. (2019) · Cancer Drug Resistance · doi:10.20517/cdr.2019.010 · Cited by 24
Resistance through repopulation
Tannock, I. F. (2014) · Nature · doi:10.1038/nature14075 · Cited by 23
High expression of NFAT2 contributes to carboplatin resistance in lung cancer
Liu, X., Pan, C., & Luo, Z. (2019) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2019.104290 · Cited by 22
Drug and Solute Transporters in Mediating Resistance to Novel Therapeutics in Multiple Myeloma
Mynott, R. L., & Wallington-Beddoe, C. T. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.1c00074 · Cited by 22
Metabolic Mechanisms of Drug Resistance in Leukemia
Knoechel, B., & Aster, J. C. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.10.005 · Cited by 21
CD44 Gene rs8193 C Allele Is Significantly Enriched in Gastric Cancer Patients.
Mokhtarian, R., Tabatabaeian, H., Saadatmand, P., Azadeh, M., Balmeh, N., Yakhchali, B., & Ghaedi, K. (2020) · PubMed Central · doi:10.22074/cellj.2020.6389 · Cited by 21
Self-citationHippo/MST blocks breast cancer by downregulating WBP2 oncogene expression via miRNA processor Dicer
Lim, S. K., Tabatabaeian, H., Lu, S. Y., Kang, S., Sundaram, G. M., Sampath, P., Chan, S. W., Hong, W. J., & Lim, Y. P. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-02901-3 · Cited by 21
Self-citationMora‐Lagos, B., Cartas‐Espinel, I., Riquelme, I., Parker, A., Piccolo, S., Viscarra, T., Reyes, M. E., Zanella, L., Buchegger, K., Ili, C., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0228331 · Cited by 20
Natural products as a means of overcoming cisplatin chemoresistance in bladder cancer
Rajendran, G., Taylor, J. A., & Woolbrigh, B. L. (2021) · Cancer Drug Resistance · doi:10.20517/cdr.2020.69 · Cited by 18
Kinahan, C., Mangone, M. A., Scotto, L., Visentin, M., Marchi, E., Cho, H. J., & O’Connor, O. A. (2020) · Oncotarget · doi:10.18632/oncotarget.27516 · Cited by 15
Ayestaran, I., Galhoz, A., Spiegel, E., Sidders, B. S., Dry, J. R., Dondelinger, F., Bender, A., McDermott, U., Iorio, F., & Menden, M. P. (2020) · Patterns · doi:10.1016/j.patter.2020.100065 · Cited by 13
Phillips, R., Lam, C., Wang, H., & Tran, P. T. (2019) · Advances in cancer research · doi:10.1016/bs.acr.2019.01.002 · Cited by 12
Öksüzoğlu, E., & Kozalak, G. (2020) · Turkish Journal of Biochemistry · doi:10.1515/tjb-2019-0521 · Cited by 6
Cited by
Molecular mechanisms and therapeutic strategies in overcoming chemotherapy resistance in cancer
Gu, Y., Yang, R., Zhang, Y., Guo, M., Takehiro, K., Zhan, M., Yang, L., & Wang, H. (2025) · Molecular Biomedicine · doi:10.1186/s43556-024-00239-2 · Cited by 184
Metadata
- Authors
- Ramos, A., Sadeghi, S., & Tabatabaeian, H.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2021-08-31
- Volume
- 22
- Issue
- 17
- Pages
- 9451
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W3197096000
- Cited by
- 289
- References
- 142
- FWCI
- 12.07
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.